Compare Cytokinetics Inc (CYTK) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Diamondback Energy Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Diamondback Energy Inc trades at $192.13 (market cap $53.67B). The key difference: Diamondback Energy Inc is far larger — about 6.2× Cytokinetics Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Diamondback Energy Inc for 69 Days on average.
| CYTK | FANG | |
|---|---|---|
Market Cap | $8.62B | $53.67B |
Volume | 2,594,626 | 2,250,644 |
Sector | Health | Energy |
52-Week High | $87.26 | $213.69 |
52-Week Low | $54.76 | $137.29 |
Typical Hold Time | 19 Days | 69 Days |
Enterprise Value | $8.72B | $65.83B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
Diamondback Energy (FANG) trades at $192.13, up 4.2% in the last session, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains solid cash flow from operations. Revenue growth is robust, with 2025 revenue reaching $14.93 billion, though net income margins have compressed. A dividend of $1.10 is scheduled for August 2026, and institutional interest remains high.
The outlook is positive with a consensus price target of $231.77, implying 20% upside. Risks include volatile oil prices and insider selling, but strong Permian Basin positioning and efficient operations support growth. Earnings on November 2, 2026, will be critical for near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
